Berger Financial Group Inc Grows Stake in Henry Schein, Inc. $HSIC

Berger Financial Group Inc lifted its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 69.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 80,790 shares of the company’s stock after buying an additional 33,070 shares during the period. Berger Financial Group Inc’s holdings in Henry Schein were worth $5,954,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the company. Assenagon Asset Management S.A. boosted its stake in shares of Henry Schein by 212.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 67,181 shares of the company’s stock valued at $5,078,000 after purchasing an additional 45,701 shares during the period. Tudor Investment Corp ET AL purchased a new stake in Henry Schein during the 3rd quarter worth $15,375,000. Kettle Hill Capital Management LLC purchased a new stake in Henry Schein during the 3rd quarter worth $14,158,000. SG Americas Securities LLC lifted its holdings in Henry Schein by 171.9% in the 4th quarter. SG Americas Securities LLC now owns 820,698 shares of the company’s stock worth $62,028,000 after buying an additional 518,914 shares in the last quarter. Finally, iSAM Funds UK Ltd acquired a new position in Henry Schein in the 3rd quarter worth $3,009,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Stock Performance

Shares of HSIC opened at $86.43 on Friday. The business’s fifty day moving average price is $77.20 and its 200 day moving average price is $77.07. Henry Schein, Inc. has a 12-month low of $61.94 and a 12-month high of $89.29. The stock has a market capitalization of $9.85 billion, a PE ratio of 26.11, a price-to-earnings-growth ratio of 1.67 and a beta of 0.81. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.36 and a quick ratio of 0.75.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The firm had revenue of $3.37 billion during the quarter, compared to the consensus estimate of $3.34 billion. During the same quarter in the previous year, the company posted $1.15 earnings per share. The firm’s revenue was up 6.3% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities research analysts forecast that Henry Schein, Inc. will post 5.32 EPS for the current year.

Insider Activity at Henry Schein

In other Henry Schein news, Director William K. Daniel acquired 10,000 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average price of $69.19 per share, with a total value of $691,900.00. Following the transaction, the director directly owned 20,000 shares in the company, valued at approximately $1,383,800. This represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.89% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Leerink Partners restated a “market perform” rating on shares of Henry Schein in a research note on Monday, March 9th. Morgan Stanley reissued an “underweight” rating and issued a $64.00 price target (up from $61.00) on shares of Henry Schein in a report on Friday, April 24th. Robert W. Baird set a $97.00 price objective on Henry Schein in a report on Wednesday, May 6th. UBS Group reaffirmed a “neutral” rating and issued a $85.00 target price (down from $87.00) on shares of Henry Schein in a research report on Wednesday, May 6th. Finally, BTIG Research upgraded Henry Schein from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a research note on Thursday, June 11th. Seven research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $87.85.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.